FDA widens OK of Novartis transplant drug

02/18/2013 | Pharmaceutical Business Review Online

Novartis' Zortress obtained FDA approval for use in the prevention of liver rejection among patients who receive the transplanted organs. The drug is already approved for kidney transplant patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ